Top

Published in:

01-08-2020 | Gastric Cancer | Research Article

A real-life analysis on the indications and prognostic relevance of perioperative chemotherapy in locally advanced resectable gastric adenocarcinoma

Authors: F. Pardo, J. Osorio, C. Miranda, S. Castro, M. Miró, A. Luna, E. Garsot, D. Momblán, G. Galofré, J. Rodríguez-Santiago, M. Pera, The Spanish EURECCA Oesophago-Gastric Cancer Group

Published in: Clinical and Translational Oncology | Issue 8/2020

Abstract

Background and purpose

Perioperative chemotherapy (periCTX) based on the “MAGIC” scheme has become a standard treatment in Europe for locally advanced oesophagogastric cancer. We assessed implementation and long-term oncological outcomes of MAGIC periCTX for locally advanced gastric cancer.

Methods

Population-based cohort study of all patients with locally advanced gastric cancer undergoing surgical resection with curative intent in Catalonia and Navarra (the first two autonomous communities included in the EURECCA Upper GI Spanish Working Group) between January 2011 and December 2013. The main variable was the percentage of patients treated with MAGIC periCTX. Kaplan–Meier analysis and Cox proportional hazards model were used to assess the survival benefit of periCTX.

Results

Among 814 patients, 217 (26.6%) received periCTX (especially patients more likely to receive it: aged < 70 years, with proximal tumors, low anesthetic risk, and cT3–4/cN+ clinical stage). 35% did not complete perioperative chemotherapy, with no relationship with age. PeriCTX showed no effect on postoperative morbimortality. Histological tumor regression was more often absent or poor (38.2%) than total or almost total (27.8%), although clinico-pathological lymph-node downstaging was higher than expected by staging inaccuracy (38.7% vs. 24.2%). PeriCTX was associated with a better survival only in cT3–4 and cN+ patients, showing less prognostic relevance than optimal oncological surgery with D2 lymphadenectomy.

Conclusions

Only 26.6% of locally advanced resectable gastric cancer patients received PeriCTX. Pathological response was poor, although some degree of nodal downstaging was observed. Survival benefit of periCTX was limited to cT3–4 and cN+ patients, being less relevant than D2 lymphadenectomy.

Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, et al. Recent patterns in gastric cancer: a global overview. Int J Cancer. 2009;125(3):666–73. https://doi.org/10.1002/ijc.24290.CrossRefPubMed

Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res. 2018;10:239–48. https://doi.org/10.2147/CMAR.S149619.CrossRefPubMedPubMedCentral

Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765–81. https://doi.org/10.1016/j.ejca.2009.12.014.CrossRef

The GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303(17):1729–37. https://doi.org/10.1001/jama.2010.534.CrossRef

Yang Y, Yin X, Sheng L, Xu S, Dong L, Liu L. Perioperative chemotherapy more of a benefit for overall survival than adjuvant chemotherapy for operable gastric cancer: an updated meta-analysis. Sci Rep. 2015;5:12850. https://doi.org/10.1038/srep12850.CrossRefPubMedPubMedCentral

Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.CrossRef

National Comprehensive Cancer Network. NCCN Clinical Practice Guideline in Oncology (NCCN Guidelines^®). Gastric Cancer. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed 25 Apr 2018.

Snyder RA, Penson DF, Ni S, Koyama T, Merchant NB. Trends in the use of evidence-based therapy for resectable gastric cancer. J Surg Oncol. 2014;110(3):285–90. https://doi.org/10.1002/jso.23635.CrossRefPubMedPubMedCentral

Al-Batran SE, Homann N, Schmalemberg H, Kopp HG, Haag GM, Luley KB, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. J Clin Oncol. 2017;35(15 suppl):4044. https://doi.org/10.1200/JCO.2017.35.15_suppl.4004.CrossRef

10.

de Steur WO, Henneman D, Allum WH, Dikken JL, van Sandick JW, Reynolds J, et al. Common data items in seven European oesophagogastric cancer surgery registries: towards a European upper GI cancer audit (EURECCA Upper GI). Eur J Surg Oncol. 2014;40(3):325–9. https://doi.org/10.1016/j.ejso.2013.11.021.CrossRefPubMed

11.

Allum W, Osorio J. EURECCA Oesophagic-Gastric Cancer Project. Cir Esp. 2016;94(5):255–6. https://doi.org/10.1016/j.ciresp.2015.CrossRefPubMed

12.

van Gijn W, van de Velde CJ, members of the EURECCA consortium. Improving quality of cancer care through surgical audit. Eur J Surg Oncol. 2010;36(Suppl 1):S23–6. https://doi.org/10.1016/j.ejso.2010.06.026.CrossRefPubMed

13.

van de Velde CJ, Aristei C, Boelens PG, Beets-Tan RG, Blomqvist L, Borras JM, et al. EURECCA colorectal: multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe. Eur J Cancer. 2013;49(13):2784–90. https://doi.org/10.1016/j.ejca.2013.04.032.CrossRefPubMed

14.

Sobin LH, Gospodarowicz M, Wittelkind C. International Union Against Cancer. TNM classification of malignant tumors. 7th ed. New York: Wiley-Blackwell; 2009. p. 84–95.

15.

American Society of Anesthesiologists. ASA physical status classification system. https://www.asahq.org/resources/clinical-information/asa-physical-status-classification-system. Accessed 27 Apr 2018.

16.

Mitsuma N, Omori Y, Miwa K. Japanese Research Society for Gastric Cancer (JRSGC). Japanese classification and guidelines of treatment of gastric cancer. 2nd ed. Tokyo: Kaneharo; 1998.

17.

Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRef

18.

Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73(11):2680–6.CrossRef

19.

Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Kieser M, Slanger TE, et al. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Cochrane Database Syst Rev. 2013. https://doi.org/10.1002/14651858.CD008107.pub2.CrossRefPubMed

20.

Lorenzen S, Blank S, Lordick F, Siewert JR, Ott K. Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients. Ann Surg Oncol. 2012;19(7):2119–27. https://doi.org/10.1245/s10434-012-2254-1.CrossRefPubMed

21.

Choi AH, Kim J, Chao J. Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond. World J Gastroenterol. 2015;21(24):7343–8. https://doi.org/10.3748/wjg.v21.i24.7343.CrossRefPubMedPubMedCentral

22.

Espallargues M, Almazán C, Tebé C, Pla R, Pons JM, Sánchez E, et al. Management and outcomes in digestive cancer surgery: design and initial results of a multicenter cohort study. Rev Esp Enferm Dig. 2009;101:680–96.CrossRef

23.

Zhu Y, Sun Y, Hu S, Jiang Y, Yue J, Xue X, et al. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China. BMC Gastroenterol. 2017;17(1):41. https://doi.org/10.1186/s12876-017-0598-5.CrossRefPubMedPubMedCentral

24.

Fareed KR, Ilyas M, Kaye PV, Soomro IN, Lobo DN, Parsons SL, et al. Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy. Hitopathology. 2009;55(4):399–406. https://doi.org/10.1111/j.1365-2559.2009.03404.x.CrossRef

25.

Mingol F, Gallego J, Orduña A, Martinez-Blasco A, Sola-Vera J, Moya P, et al. Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction. BMC Surg. 2015;15:66. https://doi.org/10.1186/s12893-015-0054-9.CrossRefPubMedPubMedCentral

26.

Kinoshita O, Ichikawa D, Ichijo Y, Komatsu S, Okamoto K, Kishimoto M, et al. Histological evaluation for chemotherapeutic responses of metastatic lymph nodes in gastric cancer. World J Gastroenterol. 2015;21(48):13500–6. https://doi.org/10.3748/wjg.v21.i48.13500.CrossRefPubMedPubMedCentral

27.

Lutz MP, Zalcberg JR, Ducreux M, Ajani JA, Allum W, Aust D, et al. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer—differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer. 2012;48(16):2941–53. https://doi.org/10.1016/j.ejca.2012.07.029.CrossRefPubMed

28.

Hu Y, Huang C, Sun Y, Su X, Cao H, Hu J, et al. Morbidity and mortality of laparoscopic versus open d2 distal gastrectomy for advanced gastric cancer: a randomized controlled trial. J Clin Oncol. 2016;34(12):1350–7. https://doi.org/10.1200/JCO.2015.63.7215.CrossRefPubMed

29.

Shrikhande SV, Barreto SG, Talole SD, Vinchurkar K, Annaiah S, Suradkar K, et al. D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy. World J Surg Oncol. 2013;11:31. https://doi.org/10.1186/1477-7819-11-31.CrossRefPubMedPubMedCentral

30.

Garg PK, Jakhetiya A, Sharma J, Ray MD, Pandey D. Lymphadenectomy in gastric cancer: contentious issues. World J Gastroenterol. 2016;8(4):294–300. https://doi.org/10.4240/wjgs.v8.i4.294.CrossRef

31.

Reece-Smith AM, Saha S, Cunnell ML, Hameed K, Bessell EM, Duffy JP, et al. MAGIC in practice: experience of peri-operative ECF/X chemotherapy in gastro-esophageal adenocarcinomas. J Surg Oncol. 2012;106(6):748–52. https://doi.org/10.1002/jso.23187.CrossRefPubMed

32.

Al-Batran SE, Homann N, Schmalenberg H, Kopp HG, Haag GM, Luley KB, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): a multicentre, randomized phase 3 trial. J Clin Oncol. 2017;35(suppl 15):4004.CrossRef

Title: A real-life analysis on the indications and prognostic relevance of perioperative chemotherapy in locally advanced resectable gastric adenocarcinoma
Authors: F. Pardo
J. Osorio
C. Miranda
S. Castro
M. Miró
A. Luna
E. Garsot
D. Momblán
G. Galofré
J. Rodríguez-Santiago
M. Pera
The Spanish EURECCA Oesophago-Gastric Cancer Group
Publication date: 01-08-2020
Publisher: Springer International Publishing
Keywords: Gastric Cancer
Gastric Cancer
Lymphadenectomy
Cytostatic Therapy
Published in: Clinical and Translational Oncology / Issue 8/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-019-02261-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background and purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2020

Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer

Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR)

Gefitinib promotes CXCR4-dependent epithelial to mesenchymal transition via TGF-β1 signaling pathway in lung cancer cells harboring EGFR mutation

Oncologic impact of micrometastases or isolated tumor cells in sentinel lymph nodes of patients with endometrial cancer: a meta-analysis

Breakthrough cancer pain: review and calls to action to improve its management

Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin

Keynote webinar | Spotlight on antibody–drug conjugates in cancer